A carregar...
Adjuvant Olaparib Improves Disease‐Free Survival in Early, High‐Risk, BRCA‐Mutated, HER2– Breast Cancer
In the phase III OlympiA trial, 1 year of adjuvant therapy with olaparib significantly improved disease‐free survival compared with placebo in patients with early ‐stage, high‐risk, BRCA‐mutated, HER2‐negative breast cancer, suggesting a new standard of care.
Na minha lista:
| Publicado no: | Oncologist |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley & Sons, Inc.
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8262311/ https://ncbi.nlm.nih.gov/pubmed/34152054 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13863 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|